Recorded on: May 14, 2026
1.5 CE Credit/Contact hours for nurses and social workers available until: January 31, 2028
1.5 CE Contact hours for nurse practitioners available until: July 31, 2027
ILNA Accredited
Format: Non-interactive recorded webinar
Target audience
This Continuing Education activity is intended for oncology nurses and nurse practitioners involved in the care of patients with hematologic malignancies.
Description
This recorded webinar is derived from ONS Congress 2026. Earn free CE credit, as you deepen your knowledge on treatment choices for blood cancers. Focus will be on when to use CAR T-cell therapy versus Stem Cell Transplant, when to refer patients for discussion of these therapies, and important questions and answers surrounding the therapy selection and sequencing in patients with blood cancer. Through case-based discussion with audience participation, the integral role of the nurse in multidisciplinary care for safe and successful provision of transplant and cellular therapies will be covered, along with resources to educate and support your patients.
Faculty
Liffy Cherian, MSN, APRN, AGCNS-BC, OCN
Clinical Nurse Specialist
Lead APP Simmons Acute Care, Infusion Services and CTU
Harold C. Simmons Comprehensive Cancer Center
UT Southwestern Medical Center
Dallas, TX
Nilesh Kalariya, PhD, AGPCNP-BC, AOCNP
Nurse Practitioner
Department of Lymphoma/Myeloma
MD Anderson Cancer Center
Houston, TX
Praveen Ramakrishnan, MD, MS, MBA, FACP
Associate Professor of Internal Medicine
Director of the Aggressive Lymphoma Program
Section of Hematologic Malignancies and Cellular Therapy, Division of Hematology/Oncology
Harold C. Simmons Comprehensive Cancer Center
UT Southwestern Medical Center
Dallas, TX
Behyar Zoghi, MD, PhD, FACP
Director of Longterm Clinic at Sarah Cannon Adult Stem cell and Cellular Therapy Program
Methodist Hospital
San Antonio, TX
Educational objectives
At the conclusion of this activity, learners should be able to:
- Describe the principles of CAR T-cell and stem cell transplantation and best practices for management in the treatment of patients with blood cancers
- Identify when to use CAR T-cell therapy versus stem cell transplant, when to refer patients, and how to appropriately sequence these modalities in clinical practice
- Explain the role of the multidisciplinary team when treating patients with CAR T-cell therapy or stem cell transplant
- Utilize educational resources on CAR T-cell therapy and stem cell transplant to support patients, caregivers, and healthcare professionals
Continuing Education information
Nursing Continuing Professional Development contact hours
Approval for nurses has been obtained by the National Office of Blood Cancer United under Provider Number CEP 5832 to award 1.5 continuing education contact hours through the California Board of Registered Nursing.
This activity is approved for 1.5 contact hour(s) of continuing education (which includes 0.75 hour(s) of pharmacology) by the American Association of Nurse Practitioners®. Activity ID# 26067873. This activity was planned in accordance with AANP Accreditation Standards and Policies.
ILNA Recertification Points
The program content has been reviewed by the Oncology Nursing Certification Corporation (ONCC) and is acceptable for recertification points in the following ILNA subject areas: Care Continuum (OCN, CBCN, CPHON, AOCNP, ROCN) 1.5*, Care of the Pediatric Hematology and Oncology Patient (CPHON) 1.5*, Foundations of Transplant/HSCT and Cellular Therapy (TCTCN) 1.5*, Oncology Nursing Practice (OCN) 1.5*, Professional Practice/Performance (TCTCN, AOCNP, ROCN) 0.5*, Treatment (AOCNP, CBCN, CPHON, OCN, ROCN) 1.5*.
Total points: 1.5
*Note that the course content applies to multiple subject areas across multiple credentials. The numerical value indicated above is the maximum amount of points that can be claimed in each subject area. The total amount of points claimed may not exceed the total amount of nursing continuing professional development (NCPD) or CME awarded from this course and may only apply to the credential you are renewing.
Provider
This activity is provided by Blood Cancer United, formerly The Leukemia & Lymphoma Society.
Support
There is no commercial support associated with this activity.
For questions, concerns, or assistance for people with disabilities or grievances, please contact us at: [email protected].